A client in need of long-term anti-inflammatory medication has been tried on NSAID and NSAID combination therapy with anti-ulcer medications, but continues to have recurring GI ulcerations. The treating physician discusses the possibility of switching to a different NSAID known as celecoxib (Celebrex), a cyclooxygenase-2 (COX-2) inhibitor. What is the nurse aware of when educating the client about the rationale for switching medications?

Question

a. The COX-2 inhibitors have the potential to cause fewer gastric problems and pose less risk of GI bleeding.
b. COX-2 inhibitors inhibit platelet aggregation (clotting).
c. Clients taking NSAIDS are not at risk for developing GI ulcers.
d. When taking COX-2 inhibitors, there is a potential for abuse or addiction.

Answer 1

a. The COX-2 inhibitors have the potential to cause fewer gastric problems and pose less risk of GI bleeding.
FEEDBACK:
a. While this medication selectively inhibits COX-2 prostaglandin synthesis, it does not inhibit COX-1 and therefore does not inhibit platelet aggregation (clotting) or the production of mucosal protective prostaglandins.
b. The COX-2 inhibitors are not known to inhibit platelet aggregation (clotting). .
c. Clients receiving long-term NSAID therapy may have a greater risk in developing GI ulcers. .
d. COX-2 inhibitors are not known to lead to abuse or addiction. .